Clinical Trial Update: To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating aliskiren for reducing albuminuria and exploring biomarkers in non-diabetic nephropathy was terminated, with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-diabetic Nephropathy

Drugs mentioned

• Aliskiren (Tekturna) (aliskiren)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-diabetic Nephropathy | Phase 2 | Status: TERMINATED | Results posted: 2013-01-30